AI Article Synopsis
- The study assessed the priorities and experiences of patients in a trial for reduced intensity treatment of HPV-positive oropharyngeal cancer.
- Out of 27 eligible patients, 89% participated, with a focus on factors like the desire to be cured and a lack of regret about their treatment decision.
- Findings indicate high patient satisfaction regarding treatment outcomes, especially in long-term swallowing function, and support the need for new treatment standards in this area.
Article Abstract
Background: We evaluated priorities, expectations, and regret among patients treated on a phase II trial of de-escalated chemoradiation for human papillomavirus (HPV)-positive oropharyngeal cancer.
Methods: Eligibility included stage III/IV squamous cell carcinoma of the oropharynx, p16-positivity, age ≥18 years, and Zubrod score 0-1. Participants were surveyed with validated measures evaluating their treatment experience.
Results: Twenty-four of 27 (89%) patients participated with a median follow-up of 24 months. Twenty-three subjects (96%) selected "being cured" or "living as long as possible" as top priority. No patient reported any regret about the decision to enroll on a de-escalation protocol. Sixteen participants (67%) found retrospectively reported long-term swallowing function to be either better than or as originally expected.
Conclusions: These data offer a baseline landscape of perspectives and priorities for patients treated with de-escalation for HPV-positive oropharyngeal carcinoma and provide support to the fundamental premise underlying ongoing efforts to establish a new standard of care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.25760 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!